Predict your next investment

Corporation
MOBILE & TELECOMMUNICATIONS | Mobile Software & Services / Payments
seamless.se

See what CB Insights has to offer

Portfolio Exits

1

Partners & Customers

7

About Seamless

Seamless (NASDAQ OMX: SEAM) is a global mobile payments company that provides prepaid top-up systems and mobile payments services for mobile operators, distributors, retailers, and consumers.

Seamless Headquarter Location

St. Eriksgatan 121

Stockholm, SE-113 43,

Sweden

+46 8 5648 7800

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Seamless

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Seamless in 1 Expert Collection, including Fintech.

F

Fintech

4,692 items

Track and capture company information and workflow.

Seamless Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Seamless Rank

Latest Seamless News

Cyclacel Pharmaceuticals Announces That Full Results From the Phase 3 Seamless Trial Have Been Selected for Oral Presentation at ASH 2017 Annual Meeting

Nov 1, 2017

November 01, 2017 09:02 ET | Source: Cyclacel BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC ) (NASDAQ: CYCCP ) (Cyclacel or the Company), a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases, announced today that data from the Company’s Phase 3 SEAMLESS study in acute myeloid leukemia, or AML, have been selected for an oral presentation at the 59th American Society of Hematology Annual Meeting in Atlanta, Georgia, on December 11, 2017. SEAMLESS is a global, randomized study evaluating a regimen of oral sapacitabine alternating with intravenous decitabine versus intravenous decitabine in elderly patients with AML who are unfit for intensive chemotherapy. Presentation details are as follows: Date and Time: Monday, December 11, 2017 at 6:45 p.m. EST Abstract Title:   Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles Session Number: 616 Publication Number: 891 Abstracts for the 2017 ASH Annual Meeting can be accessed at: http://www.hematology.org/Annual-Meeting/ . About Cyclacel Pharmaceuticals, Inc. Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com . Forward-looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts Investor Relations:  Alexander Fudukidis, Russo partners LLC, (646) 942-5632, alex.fudukidis@russopartnersllc.com © Copyright 2017 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc. Related Articles

Seamless Portfolio Exits

1 Portfolio Exit

Seamless has 1 portfolio exit. Their latest portfolio exit was MeaWallet on March 26, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

3/26/2019

Management Buyout

1

Date

3/26/2019

Exit

Management Buyout

Companies

Valuation

Acquirer

Sources

1

Seamless Acquisitions

2 Acquisitions

Seamless acquired 2 companies. Their latest acquisition was Riaktr on May 06, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/6/2021

Series A

$99M

$13.5M

Acquired

1

7/13/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/6/2021

7/13/2016

Investment Stage

Series A

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$13.5M

Note

Acquired

Subscribe to see more

Sources

1

10

Seamless Partners & Customers

7 Partners and customers

Seamless has 7 strategic partners and customers. Seamless recently partnered with Raiffeisen Bank International on June 6, 2016.

Date

Type

Business Partner

Country

News Snippet

Sources

6/2/2016

Client

Austria

Seamless Distribution AB: Raiffeisen Bank to Launch SEQR in Romania

Nasdaq Stockholm-listed Seamless has signed an agreement with Raiffeisen Bank International via its SEQR subsidiary .

1

2/3/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/27/2015

Partner

United States

Subscribe to see more

Subscribe to see more

10

10/22/2015

Vendor

Norway

Subscribe to see more

Subscribe to see more

10

6/25/2015

Partner

France

Subscribe to see more

Subscribe to see more

10

Date

6/2/2016

2/3/2016

11/27/2015

10/22/2015

6/25/2015

Type

Client

Partner

Partner

Vendor

Partner

Business Partner

Country

Austria

United States

United States

Norway

France

News Snippet

Seamless Distribution AB: Raiffeisen Bank to Launch SEQR in Romania

Nasdaq Stockholm-listed Seamless has signed an agreement with Raiffeisen Bank International via its SEQR subsidiary .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Seamless Team

3 Team Members

Seamless has 3 team members, including former Chief Executive Officer, Rohit Bhatia.

Name

Work History

Title

Status

Rohit Bhatia

Chief Executive Officer

Former

Craig J Holden

Chief Financial Officer

Former

Daniel Nyholm

Chief Financial Officer

Former

Name

Rohit Bhatia

Craig J Holden

Daniel Nyholm

Work History

Title

Chief Executive Officer

Chief Financial Officer

Chief Financial Officer

Status

Former

Former

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.